Core Insights - The data from the National Cancer Center indicates that over 350,000 new breast cancer cases were reported in China in 2022, posing a significant threat to women's health [1] - The implementation of the new medical insurance directory on January 1, 2026, will include 8 new drugs for breast cancer and expand the indications for 2 existing drugs, increasing access to innovative treatments for more patients [1] Group 1 - The most common molecular subtype of breast cancer is HR+/HER2- (hormone receptor positive, HER2 negative), accounting for approximately 80% of all breast cancer patients [1] - Endocrine therapy, including targeted endocrine drugs, is crucial for both early and late-stage breast cancer patients, as highlighted by experts in the field [1] Group 2 - Resistance to endocrine therapy is often linked to the activation of the PAM pathway, particularly mutations in genes such as PIK3CA and AKT, which limit subsequent treatment options for patients [2] - The inclusion of targeted PAM pathway drugs in the medical insurance directory significantly reduces the financial burden on patients, making innovative treatments more accessible [2] Group 3 - Early detection and timely diagnosis of different clinical subtypes of breast cancer, along with personalized treatment plans, can significantly extend survival time and improve the quality of life for patients [3] - A multidisciplinary treatment approach is essential for breast cancer management, integrating evidence-based medicine, expert experience, and patient preferences to enhance treatment outcomes and optimize resource utilization [3]

Group 1: Cancer Prevention and Health Education - The 31st National Cancer Prevention and Control Publicity Week emphasizes the theme "Scientific Cancer Prevention, Healthy Living" [1] - Jiangsu Provincial People's Hospital advocates for a health-centered approach to cancer prevention, focusing on health education and improving public health literacy [1] - The hospital suggests integrating health education into its development plan, establishing dedicated health education departments, and enhancing the scientific literacy of medical staff through training [1] Group 2: Comprehensive Cancer Care - Jiangsu Provincial People's Hospital adopts a multidisciplinary treatment model, establishing specialized centers for lymphoma, gastric tumors, and thyroid cancer to manage patient care throughout the entire process [2] - The hospital has upgraded traditional treatment processes to full-cycle rehabilitation management, incorporating resources from traditional Chinese medicine, nutrition, and rehabilitation [2] - The complexity of lymphoma, with over 100 pathological subtypes, necessitates precise diagnosis and individualized treatment plans, focusing on pre-hospital assessments and post-discharge home management [2] Group 3: Research and Innovation in Cancer Treatment - There is a call for increased research into the mechanisms of lymphoma and drug resistance, as well as the exploration of clinical translation pathways [2] - Advances in basic research have led to the development of innovative therapies such as monoclonal antibodies, bispecific antibodies, and cell therapies, significantly improving clinical outcomes for lymphoma patients [2] - The goal is to translate research and clinical experiences into innovative drugs that effectively serve patients with hematological diseases and lymphomas [2]